United Kingdom· GB-APID-42779811000001107
Erleada 240mg tablets
A apalutamide product containing apalutamide, registered in United Kingdom by Janssen-Cilag Ltd. The same ATC class is registered in 15 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Apalutamide is registered in 15 of 19 countries.
Countries holding a registration under ATC L02BB05 (apalutamide), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Apalutamide · ATC L02BB05
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of apalutamide costs, country by country.
Normalised to the WHO defined daily dose (0.24 g), the median price runs from $0.094 in France to $370.27 in Switzerland — a ×3935 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Apalutamide · price per daily dose (0.24 g)
USD · FX 28 Sept 2026
- CH Switzerland$370.27
- FR France$0.094
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Apalutamide
- Manufacturer
- Janssen-Cilag Ltd
- Country
- United Kingdom (GB)
- ATC code
- L02BB05
- ATC class
- Apalutamide
- Defined daily dose
- 0.24 g, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin05012674904275
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
670 interactions on record for apalutamide.
Graded by severity as the source publishes them — 244 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Apalutamide · interactions on record
670 records
- 244 severe
- 412 moderate
- 14 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- RolapitantA04AD14severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Apalutamide in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaERLEADAJANSSEN INC
- CzechiaERLEADAJanssen-Cilag International N.V., Beerse
- SpainERLEADA 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULAJanssen-Cilag International N.V
- United StatesERLEADAJanssen Products, LP
- FinlandErleadaJanssen-Cilag International NV
- FranceERLEADA 240 mg, comprimés pelliculésJANSSEN CILAG INTERNATIONAL NV
- IrelandErleada 240 mg film-coated tabletsJanssen-Cilag International NV
- IcelandErleadaJanssen-Cilag International NV*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Erleada
- Liechtenstein · Erleada
- Norway · Erleada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dd1a604d-5e25-451d-b33c-2b16dad0a031 GET /v1/drugs/dd1a604d-5e25-451d-b33c-2b16dad0a031?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "42779811000001107",
"desc": "Erleada 240mg tablets (Janssen-Cilag Ltd)",
"form": "Oral tablet",
"vpid": "42783211000001101",
"source": "dmd",
"vtm_id": "774623008",
"strength": "240 mg",
"substance": "Apalutamide",
"ingredient": "Apalutamide",
"supplier_code": "2422501000001106"
}See everything about apalutamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.